Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

NCT00237198 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Women With Advanced Breast Cancer

Interventions

DRUG: Letrozole

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]